Immorta Bio, SenoMune-0257, AI-Designed Immunotherapy, Senolytic Therapy, Cellular Senescence, Aging Research, Peptide Therapeutics, Artificial Intelligence in Drug Discovery

Sarasota, Florida, U.S., October 13, 2026 Immorta Bio, Inc. has announced progress in its development of an artificial intelligence...